Squarepoint’s Bio-Techne TECH Stock Holding History

Squarepoint’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,900	Closed	-$2.31M	–	4606
2023 Q4	$2.31M	Buy	+29,900	New	+$1.97M	﹤0.01%	1902

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Squarepoint's TECH Position: Q2 2026 in Review

Squarepoint increased its Bio-Techne (TECH) stake by 2,094% in Q2 2026, buying an estimated $4.7M and bringing the position to 91,268 shares worth $6.45M. The position accounts for 0.01% of the portfolio, ranked #1386.

Squarepoint first reported a position in TECH in Q4 2017 and has held it in 30 quarters since. The position peaked at $25.4M in Q2 2025. 596 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

Squarepoint held 91,268 shares of Bio-Techne worth $6.45M as of Q2 2026.
Squarepoint bought 87,109 Bio-Techne shares in Q2 2026, an estimated $4.7M.
Bio-Techne made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1386 holding.
Squarepoint first reported a position in Bio-Techne in Q4 2017 and has held it in 30 quarters since.
Squarepoint's Bio-Techne position peaked at $25.4M in Q2 2025.
596 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.